Literature DB >> 32419563

Safety of dupilumab in atopic patients during COVID-19 outbreak.

Maddalena Napolitano1, Cataldo Patruno2, Angelo Ruggiero3, Mariateresa Nocerino3, Gabriella Fabbrocini3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32419563     DOI： 10.1080/09546634.2020.1771257

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN： 0954-6634            Impact factor:   3.359


× No keyword cloud information.
  12 in total

1.  Impact of COVID-19 on patients with atopic dermatitis.

Authors:  Teresa Grieco; Camilla Chello; Alvise Sernicola; Rovena Muharremi; Simone Michelini; Giovanni Paolino; Giorgia Carnicelli; Paolo Daniele Pigatto
Journal:  Clin Dermatol       Date:  2021-07-17       Impact factor: 3.541

Review 2.  Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge.

Authors:  Angelo Ruggiero; Luca Potestio; Elisa Camela; Gabriella Fabbrocini; Matteo Megna
Journal:  Psoriasis (Auckl)       Date:  2022-06-08

3.  Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment-a population-based cohort study.

Authors:  Khalaf Kridin; Yochai Schonmann; Arie Solomon; Erez Onn; Dana Tzur Bitan; Orly Weinstein; Arnon D Cohen
Journal:  Immunol Res       Date:  2021-10-13       Impact factor: 2.829

Review 4.  Dupilumab therapy in atopic dermatitis is safe during COVID-19 infection era: A systematic review and meta-analysis of 1611 patients.

Authors:  Amr Ehab El-Qushayri; Mariam Abdelmageed Mahmoud; Samar Salman; Sameh Sarsik; Beatrice Nardone
Journal:  Dermatol Ther       Date:  2022-04-07       Impact factor: 3.858

5.  Reply to "the significance of investigating clinical, histopathologic and virological features in pityriasis rosea and pityriasis rosea-like eruptions following COVID-19 vaccinations" by Ciccarese G. et al.

Authors:  Fabrizio Martora; Vincenzo Picone; Teresa Battista; Gabriella Fabbrocini; Claudio Marasca
Journal:  Dermatol Ther       Date:  2022-06-13       Impact factor: 3.858

Review 6.  Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.

Authors:  Angelo Ruggiero; Vincenzo Picone; Fabrizio Martora; Gabriella Fabbrocini; Matteo Megna
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-16

7.  Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study.

Authors:  Matteo Megna; Luca Potestio; Gabriella Fabbrocini; Angelo Ruggiero
Journal:  Psoriasis (Auckl)       Date:  2022-07-14

8.  Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry.

Authors:  Andrea Chiricozzi; Marina Talamonti; Clara De Simone; Marco Galluzzo; Niccolò Gori; Gabriella Fabbrocini; Angelo Valerio Marzano; Giampiero Girolomoni; Annamaria Offidani; Maria Teresa Rossi; Luca Bianchi; Antonio Cristaudo; Maria Teresa Fierro; Luca Stingeni; Giovanni Pellacani; Giuseppe Argenziano; Annalisa Patrizi; Paolo Pigatto; Marco Romanelli; Paola Savoia; Pietro Rubegni; Caterina Foti; Nicola Milanesi; Anna Belloni Fortina; Maria Rita Bongiorno; Teresa Grieco; Sergio Di Nuzzo; Maria Concetta Fargnoli; Andrea Carugno; Alberico Motolese; Franco Rongioletti; Paolo Amerio; Riccardo Balestri; Concetta Potenza; Giuseppe Micali; Cataldo Patruno; Iris Zalaudek; Maurizio Lombardo; Claudio Feliciani; Lucia Di Nardo; Fabrizio Guarneri; Ketty Peris
Journal:  Allergy       Date:  2021-03-09       Impact factor: 13.146

Review 9.  Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications.

Authors:  Claudio Marasca; Maria Carmela Annunziata; Elisa Camela; Adriana Di Guida; Luigi Fornaro; Matteo Megna; Maddalena Napolitano; Cataldo Patruno; Luca Potestio; Gabriella Fabbrocini
Journal:  J Clin Med       Date:  2022-03-10       Impact factor: 4.241

10.  Dupilumab in atopic dermatitis, a protocol for SARS-COV-2-infected patients.

Authors:  Maria Fernanda Ordóñez-Rubiano; Isabela Campo; Mirian Casas
Journal:  Dermatol Ther       Date:  2020-09-05       Impact factor: 3.858
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.